Skip to content

Testing the Engaged Approach to Lung Cancer Screening

Feasibility Testing the Engaged Approach to Lung Cancer Screening

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06327074
Enrollment
40
Registered
2024-03-25
Start date
2024-03-11
Completion date
2026-12-31
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The goal of this study is to assess feasibility and acceptability of the Engaged Approach to Lung Cancer Screening (EA-LCS) in diverse lung cancer screening (LCS) programs operating in a variety of geographic regions across Colorado and the US.

Interventions

BEHAVIORALEngaged Approach to Lung Cancer Screening

Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials. Staff-facing materials include: * Program website/manual/toolkit overview * Implementation insights with experts video series * Clinical placement placards * Program and clinician communication tools Candidate-facing materials include: * Program welcome letter * Maps and directions template * Communication preferences * Candidate letter templates (N=\ 8) * Program newsletter template and instructions * Lung nodule size comparison chart

Sponsors

Bristol-Myers Squibb
CollaboratorINDUSTRY
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

The trial incorporates a multilevel assessment and enrollment involves inclusion criteria at two levels: (1) LCS Program and (2) LCS Program Staff member. Program inclusion criteria (n = up to 8 sites): * Must conduct at least 50 low-dose computed tomography (LDCT) scans per year (baseline + follow-up) * Must be able to identify a primary contact person for LCS program operations (e.g., program coordinator, program navigator, program manager, etc.) Staff member inclusion criteria (n \ 5 at each site/\ 40 participants total): * Identified staff member of the LCS program site * \>18 years of age * Must be able to complete study surveys and interviews in English * Willing to provide informed consent

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
Percentage of the intervention group who would like to continue the EA-LCS framework7 months
Percentage of the intervention group who would recommend the EA-LCS framework to other programs7 months
Percentage of participants who would describe the framework as workable7 months

Secondary

MeasureTime frameDescription
Evaluate the intervention acceptability by Acceptability of Intervention Measure (AIM)12 monthsIndexes of intervention acceptability will be measured by the Acceptability of Intervention Measure (AIM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean.
Evaluate the intervention appropriateness by Intervention Appropriateness Measure (IAM)12 monthsIndexes of intervention appropriateness will be measured by the Intervention Appropriateness Measure (IAM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean.
Evaluate the intervention feasibility by Feasibility of Intervention Measure (FIM)12 monthsIndexes of intervention feasibility will be measured by the Feasibility of Intervention Measure (FIM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026